↓ Skip to main content

Dove Medical Press

Article Metrics

Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial

Overview of attention for article published in Drug Design, Development and Therapy, July 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
84 Mendeley
Title
Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial
Published in
Drug Design, Development and Therapy, July 2013
DOI 10.2147/dddt.s45575
Pubmed ID
Authors

Narong Maneeton, Benchalak Maneeton, Srisurapanon, Kaweesak Chittawatanarat

Abstract

Atypical antipsychotic drugs may have low propensity to induce extrapyramidal side effects in delirious patients. This study aimed to compare the efficacy and tolerability between quetiapine and haloperidol in controlling delirious behavior.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Korea, Republic of 1 1%
Unknown 82 98%

Demographic breakdown

Readers by professional status Count As %
Other 13 15%
Researcher 12 14%
Student > Doctoral Student 9 11%
Student > Master 9 11%
Professor > Associate Professor 8 10%
Other 32 38%
Unknown 1 1%
Readers by discipline Count As %
Medicine and Dentistry 53 63%
Unspecified 10 12%
Nursing and Health Professions 5 6%
Agricultural and Biological Sciences 4 5%
Psychology 4 5%
Other 7 8%
Unknown 1 1%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2015.
All research outputs
#2,026,072
of 5,422,669 outputs
Outputs from Drug Design, Development and Therapy
#127
of 817 outputs
Outputs of similar age
#34,587
of 109,695 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 35 outputs
Altmetric has tracked 5,422,669 research outputs across all sources so far. This one has received more attention than most of these and is in the 62nd percentile.
So far Altmetric has tracked 817 research outputs from this source. They receive a mean Attention Score of 2.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,695 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.